NVTA - US Court Prohibits NeoGenomics To Sell Type Of Diagnostic Kits To Detect Smaller Number Of Cancer Cells Favoring Natera In Lawsuit | Benzinga
Shares of NeoGenomics Inc (NASDAQ: NEO) fell Thursday after the company received a preliminary injunction from a North Carolina district court, which prohibits the company from selling its RaDaR technology.
In the suit, Natera Inc (NASDAQ: NTRA) alleged that NeoGenomics' RaDaR infringed on Natera's patent.
NeoGenomics said in a statement Thursday morning that the company plans to appeal the ruling.
The injunction bars NeoGenomics from "making, using, selling, or offering for sale in the U.S… the accused RaDaR assay" ...